The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles

Blood Adv. 2018 Jan 23;2(2):76-84. doi: 10.1182/bloodadvances.2017012971.

Abstract

Sequestering of latent HIV in follicular helper T cells within B-cell follicles that largely exclude cytotoxic T cells is a major barrier to cellular immune-based approaches to eradicate HIV. Here, we show that the clinical-grade human interleukin-15 (IL-15) superagonist ALT-803 activates and redirects simian immunodeficiency virus (SIV)-specific CD8+ T cells from the peripheral blood into B-cell follicles. In agreement with the increased trafficking of SIV-specific cytotoxic T cells to sites of cryptic viral replication, lymph nodes of elite controlling macaques contained fewer cells expressing SIV RNA or harboring SIV DNA post-ALT-803 treatment. These data establish ALT-803 as an immunotherapeutic for HIV and other chronic viral pathogens that evade host immunity by persisting in B-cell follicles.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • B-Lymphocytes / virology*
  • CD8-Positive T-Lymphocytes / immunology*
  • HIV / drug effects
  • Humans
  • Immune Evasion / drug effects
  • Interleukin-15 / agonists
  • Macaca / virology
  • Proteins / therapeutic use*
  • Recombinant Fusion Proteins
  • Simian Immunodeficiency Virus / immunology*
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • ALT-803
  • Interleukin-15
  • Proteins
  • Recombinant Fusion Proteins